| Drug Name | Vokanamet (Canagliflozin, Metformin) |
|---|---|
| Drug Class |
Anti-diabetic
|
| Risk minimization type |
Direct Healthcare Professional Communication DHPC
Safety communication
|
| Specialty (Theraputic area) |
Endocrine
|
| Risk |
Risk of contrast-induced nephropathy associated with the use of metformin and contrast agents |
| safety communication |
|
| Dear Healthcare provider letter DHPC |
|